Chih-Wei Hung1, Chao-Lun Lai2, Mu-Yang Hsieh1, Ruei-Cheng Kuo3, Kuei-Chin Tsai1, Lin Lin1, Chih-Cheng Wu4. 1. Department of Cardiology, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan; 2. Department of Cardiology, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan; ; College of Medicine, National Taiwan University, Taipei, Taiwan; 3. Department of Radiology, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan. 4. Department of Cardiology, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan; ; School of Medicine, Yang-Ming University, Taipei, Taiwan; ; College of Medicine, National Taiwan University, Taipei, Taiwan;
Abstract
BACKGROUND: To investigate the efficacy, safety, and patency following treatment of wall-adherent thrombus in hemodialysis vascular access with a wall-contact device, the Arrow-Trerotola percutaneous thrombolytic device (PTD). METHODS: We retrospectively reviewed an existing database of procedures fulfilling the following criteria: thrombosed hemodialysis access, wall-adherent thrombus, and use of PTD for mechanical thrombectomy. Data on immediate success, complications, and patency were collected from medical records, dialysis records, and angiographic reports. RESULTS: Ninety-three patients with 108 episodes of vascular access thrombosis were included in the study. Fifty-three of the procedures were performed on native fistulas, and 55 were on synthetic grafts. Anatomical and clinical success was achieved in 97% and 96% of the procedures, respectively. The average procedure time was 52 ± 23 minutes. Complications occurred in three of the procedures (2.7%), but none of these complications were device-related. The primary patency rates in the native fistula group were 57% and 42% at three and six months, respectively. The primary patency rates in the synthetic graft group were 40% at three months, and 27% at six months. The secondary patency rates at six months were 91% in the native fistula group, and 93% in the synthetic graft group. CONCLUSIONS: Our results show that a wall-contact mechanical device, PTD, is effective and safe for endovascular removal of wall-adherent thrombi in hemodialysis vascular access in both native fistulas and synthetic grafts. KEY WORDS: Adherent; Angioplasty; Endovascular; Hemodialysis; Thrombectomy; Vascular access.
BACKGROUND: To investigate the efficacy, safety, and patency following treatment of wall-adherent thrombus in hemodialysis vascular access with a wall-contact device, the Arrow-Trerotola percutaneous thrombolytic device (PTD). METHODS: We retrospectively reviewed an existing database of procedures fulfilling the following criteria: thrombosed hemodialysis access, wall-adherent thrombus, and use of PTD for mechanical thrombectomy. Data on immediate success, complications, and patency were collected from medical records, dialysis records, and angiographic reports. RESULTS: Ninety-three patients with 108 episodes of vascular access thrombosis were included in the study. Fifty-three of the procedures were performed on native fistulas, and 55 were on synthetic grafts. Anatomical and clinical success was achieved in 97% and 96% of the procedures, respectively. The average procedure time was 52 ± 23 minutes. Complications occurred in three of the procedures (2.7%), but none of these complications were device-related. The primary patency rates in the native fistula group were 57% and 42% at three and six months, respectively. The primary patency rates in the synthetic graft group were 40% at three months, and 27% at six months. The secondary patency rates at six months were 91% in the native fistula group, and 93% in the synthetic graft group. CONCLUSIONS: Our results show that a wall-contact mechanical device, PTD, is effective and safe for endovascular removal of wall-adherent thrombi in hemodialysis vascular access in both native fistulas and synthetic grafts. KEY WORDS: Adherent; Angioplasty; Endovascular; Hemodialysis; Thrombectomy; Vascular access.
Authors: L Turmel-Rodrigues; M Sapoval; J Pengloan; L Billaux; D Testou; S Hauss; A Mouton; D Blanchard Journal: J Vasc Interv Radiol Date: 1997 Sep-Oct Impact factor: 3.464
Authors: Josh B Shatsky; Jeffrey S Berns; Timothy W I Clark; Andrew Kwak; Catherine M Tuite; Richard D Shlansky-Goldberg; Jeffrey I Mondschein; Aalpen A Patel; S William Stavropoulos; Michael C Soulen; Jeffrey A Solomon; Sidney Kobrin; Jesse L Chittams; Scott O Trerotola Journal: J Vasc Interv Radiol Date: 2005-12 Impact factor: 3.464
Authors: Shahriar Moossavi; John D Regan; Eric D Pierson; John M Kasey; Audrey B Tuttle; Tushar J Vachharajani; Michael A Bettmann; Gregory B Russell; Barry I Freedman Journal: Semin Dial Date: 2007 Sep-Oct Impact factor: 3.455
Authors: José García-Medina; Ana B Maldonado-Cárceles; Juan J García-Alfonso; Julián J Árense-Gonzalo; Alberto M Torres-Cantero Journal: Clin Kidney J Date: 2020-02-10